一种灭活SARS-CoV-2疫苗(BBV152)的 efficacy、安全性和批间免疫原性:随机、双盲、对照3期试验的中期结果
在印度25家医院开展的随机双盲安慰剂对照3期试验中,25798名成人随机分配接种BBV152或安慰剂,两剂间隔4周。在16973名基线血清阴性参与者中,疫苗组有症状COVID-19病例24例(0.3%),安慰剂组106例(1.2%),总体疫苗 efficacy 为77.8%(95%CI 65.2-86.4)。安全性人群中疫苗组与安慰剂组不良事件报告比例均为12.4%,未发现安全 concerns。
要点
- BBV152对实验室确诊的有症状COVID-19总体 efficacy 为77.8%(95%CI 65.2-86.4)。
- 疫苗组与安慰剂组不良事件报告比例均为12.4%,无过敏反应或疫苗相关死亡。
- 两剂间隔4周,中期分析中位随访99天。
核心结论
- BBV152对成人实验室确诊的有症状COVID-19具有高 efficacy。
- 接种耐受性良好,本次中期分析未提出安全 concerns。
研究设计与样本
- 在印度25家医院或医疗诊所开展的随机、双盲、安慰剂对照、多中心3期临床试验。
- 招募25798名≥18岁健康或慢性病稳定的成人,按1:1随机分配接种两剂BBV152或安慰剂,间隔4周。
- 主要结局为符合方案人群中第二剂后至少14天首次发生实验室确诊(RT-PCR阳性)有症状COVID-19(任何严重程度)的 efficacy。
- 安全性在全部至少接种一剂疫苗或安慰剂的参与者中评估。
- 本报告为中期结果,数据截止2021年5月17日,免疫原性和安全性数据采集于第0至56天, efficacy 结果中位随访99天。
主要发现
- 2020年11月16日至2021年1月7日招募25798名参与者随机分配,其中24419名接种两剂BBV152(n=12221)或安慰剂(n=12198)。
- 在16973名基线血清阴性参与者中,疫苗组8471人中有24例(0.3%)有症状COVID-19,安慰剂组8502人中有106例(1.2%),总体疫苗 efficacy 77.8%(95%CI 65.2-86.4)。
- 安全性人群(n=25753)中,3194名参与者发生5959起不良事件。
- 疫苗组不良事件报告比例为12.4%(1597/12879),安慰剂组为12.4%(1597/12874),两组间 solicited、unsolicited 或严重不良事件分布无临床显著差异。
- 未发生过敏反应或疫苗相关死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults. METHODS: We did a randomised, double-blind, placebo-controlled, multicentre, phase 3 clinical trial in 25 Indian hospitals or medical clinics to evaluate the efficacy, safety, and immunological lot consistency of BBV152. Adults (age ≥18 years) who were healthy or had stable chronic medical conditions (not an immunocompromising condition or requiring treatment with immunosuppressive therapy) were randomised 1:1 with a computer-generated randomisation scheme (stratified for the presence or absence of chronic conditions) to receive two intramuscular doses of vaccine or placebo administered 4 weeks apart. Participants, investigators, study coordinators, study-related personnel, the sponsor, and nurses who administered the vaccines were masked to treatment group allocation; an unmasked contract research organisation and a masked expert adjudication panel assessed outcomes. The primary outcome was the efficacy of the BBV152 vaccine in preventing a first occurrence of laboratory-confirmed (RT-PCR-positive) symptomatic COVID-19 (any severity), occurring at least 14 days after the second dose in the per-protocol population. We also assessed safety and reactogenicity throughout the duration of the study in all participants who had received at least one dose of vaccine or placebo. This report contains interim results (data cutoff May 17, 2021) regarding immunogenicity and safety outcomes (captured on days 0 to 56) and efficacy results with a median of 99 days for the study population. The trial was registered on the Indian Clinical Trials Registry India, CTRI/2020/11/028976, and ClinicalTrials.gov, NCT04641481 (active, not recruiting). FINDINGS: Between Nov 16, 2020, and Jan 7, 2021, we recruited 25 798 participants who were randomly assigned to receive BBV152 or placebo; 24 419 received two doses of BBV152 (n=12 221) or placebo (n=12 198). Efficacy analysis was dependent on having 130 cases of symptomatic COVID-19, which occurred when 16 973 initially seronegative participants had at least 14 days follow-up after the second dose. 24 (0·3%) cases occurred among 8471 vaccine recipients and 106 (1·2%) among 8502 placebo recipients, giving an overall estimated vaccine efficacy of 77·8% (95% CI 65·2-86·4). In the safety population (n=25 753), 5959 adverse events occurred in 3194 participants. BBV152 was well tolerated; the same proportion of participants reported adverse events in the vaccine group (1597 [12·4%] of 12 879) and placebo group (1597 [12·4%] of 12 874), with no clinically significant differences in the distributions of solicited, unsolicited, or serious adverse events between the groups, and no cases of anaphylaxis or vaccine-related deaths. INTERPRETATION: BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. Vaccination was well tolerated with no safety concerns raised in this interim analysis. FUNDING: Bharat Biotech International and Indian Council of Medical Research.
引用
- Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021. PMID: 34774196. doi:10.1016/S0140-6736(21)02000-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。